Skip to main content

Relay Therapeutics, Inc.

corporate_fare Company Profile

Relay Therapeutics, Inc.

RLAY·NASDAQ·Life Sciences·CIK 0001812364

We are a clinical-stage, small molecule precision medicine company developing therapies for patients with cancer and genetic disease. Our Dynamo® platform integrates computational and experimental approaches to drug protein targets that have been difficult to address. Precision medicine aims to drug genetically validated target proteins, but some have been intractable with conventional drug discovery tools. Our approach shifts from a static view of protein targets to one based on protein motion, which we term Motion-Based Drug Design®. We apply these insights to drug discovery and design. We have used our technology platform to build a pipeline of product candidates for precision medicine targets where there is clear evidence linking target proteins to disease and where molecular diagnostics can identify relevant patients. We are advancing a pipeline of medicine candidates for precision oncology and genetic disease, including zovegalisib (RLY-2608). Zovegalisib (RLY-2608) is the first known allosteric, pan-mutant and isoform-selective phosphoinostide 3 kinase alpha, or PI3Kα, inhibitor in clinical development. It is the lead program in our efforts to discover and develop mutant selective inhibitors of PI3Kα, targeting Breast Cancer and Solid Tumors in the ReDiscover Trial.

Relay Therapeutics, Inc. (NASDAQ:RLAY) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 27 items for RLAY at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-11-04, rated 7/10. Across its 20 most recent items scored 7 or higher, the top rating is 9/10, with 13 rated 8 or above. Recent SEC coverage for RLAY spans 10-Q, 144, 424B5, 8-K.

Recent high-impact activity:

  • Relay 10-Q: $848.6M Cash Into 2029, Q3 Loss $81.7M, ATM Upsized to $463M
  • Relay Posts $848.6M Cash, Accelerates Breast Cancer Enrollment to Mid-2027
  • Relay Therapeutics Hits Phase 3 Milestone in X-Chem Collaboration
  • SVF Pauling (Cayman) Files to Sell 6M Shares of Relay Therapeutics (~$123M)
  • Relay Therapeutics Upsizes ATM Program to $463M, Adding $213M in New Capacity

Financial Snapshot

Fiscal year ended December 31, 2025
Revenue
$15.36M
Net Income
-$276.48M
Diluted EPS
-$1.61
Op. Cash Flow
-$235.46M
Free Cash Flow
-$235.87M
Operating Income
-$302.74M
Cash & Equivalents
$84.02M
Debt / Equity
0.00×
Net Margin
-18.01×
Shares Outstanding
173.87M sh
Source: 10-K · filed 2026-02-26 · accession 0001193125-26-076739

Short Interest & Short Volume

20.72 days to cover

FINRA reported short interest of 43,629,223 shares in RLAY as of the October 30, 2026 settlement, a 0.9% decrease from the prior period — about 20.7 days to cover at its recent average daily volume. On November 20, 2026, 62.4% of RLAY volume reported to FINRA trade-reporting facilities was marked short.

Short interest (bi-monthly positions)43,629,223 shares as of October 30, 2026
Change vs prior period▼ 0.9%
Days to cover20.72 at avg daily volume of 2,105,321
Daily short volume (FINRA facilities)62.4% of 1,847,486 shares on November 20, 2026
5-day average short volume54.5%

Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.

Dilution Risk

Moderate risk

Filing-implied dilution signals for RLAY, detected from its recent SEC filings · based on capital-structure filings through 2026-08-06.

1 recent capital raiseATM program

Authorized Shares Increased · Significant Potential Dilution

A filing-implied signal, not a realized share count. How Wiseek tracks dilution →

Browse all tickers starting with R →
$16.19 +0.46% today
52-week range · as of 2026-11-04 $5.95 – $21.27
Market cap
$3.56B
Volume
4M (1.6× avg)
3-mo avg 2.5M
Live data · 2026-11-22 08:52 UTC · Market closed

show_chartPrice Chart

Loading chart...

feed RLAY - Latest Insights

RLAY
Nov 04, 2026, 4:15 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $18.02
Real-time Price: $16.19 info
Change: -$1.83 (-10%) info
Market Cap: $3.562B info
RLAY
Nov 04, 2026, 4:05 PM EST
Source: GlobeNewswire
Importance Score:
7
Price at Filing: $18.02
Real-time Price: $16.19 info
Change: -$1.83 (-10%) info
Market Cap: $3.562B info
RLAY
Sep 22, 2026, 11:23 AM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $18.54
Real-time Price: $16.19 info
Change: -$2.35 (-13%) info
Market Cap: $3.562B info
RLAY
Aug 25, 2026, 7:43 PM EDT
Filing Type: 144
Importance Score:
7
Price at Filing: $19.88
Real-time Price: $16.19 info
Change: -$3.69 (-19%) info
Market Cap: $3.562B info
RLAY
Aug 06, 2026, 4:41 PM EDT
Filing Type: 424B5
Importance Score:
7
Price at Filing: $19.30
Real-time Price: $16.19 info
Change: -$3.11 (-16%) info
Market Cap: $3.562B info
RLAY
Aug 06, 2026, 4:40 PM EDT
Source: Reuters
Importance Score:
8
Price at Filing: $19.04
Real-time Price: $16.19 info
Change: -$2.85 (-15%) info
Market Cap: $3.562B info
RLAY
Aug 06, 2026, 4:11 PM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $19.75
Real-time Price: $16.19 info
Change: -$3.56 (-18%) info
Market Cap: $3.562B info
RLAY
Jun 09, 2026, 4:35 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $14.09
Real-time Price: $16.19 info
Change: +$2.10 (+15%) info
Market Cap: $3.562B info
RLAY
May 21, 2026, 5:13 PM EDT
Source: Wiseek News
Importance Score:
8
Price at Filing: $13.87
Real-time Price: $16.19 info
Change: +$2.32 (+17%) info
Market Cap: $3.562B info
RLAY
May 21, 2026, 5:07 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $13.72
Real-time Price: $16.19 info
Change: +$2.47 (+18%) info
Market Cap: $3.562B info
RLAY
May 21, 2026, 4:12 PM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $13.55
Real-time Price: $16.19 info
Change: +$2.64 (+20%) info
Market Cap: $3.562B info
RLAY
May 20, 2026, 8:21 PM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $13.18
Real-time Price: $16.19 info
Change: +$3.01 (+23%) info
Market Cap: $3.562B info
RLAY
May 19, 2026, 5:15 PM EDT
Filing Type: 424B5
Importance Score:
8
Price at Filing: $11.66
Real-time Price: $16.19 info
Change: +$4.53 (+39%) info
Market Cap: $3.562B info
RLAY
May 19, 2026, 4:03 PM EDT
Source: GlobeNewswire
Importance Score:
8
Price at Filing: $11.92
Real-time Price: $16.19 info
Change: +$4.27 (+36%) info
Market Cap: $3.562B info
RLAY
May 19, 2026, 8:45 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $13.44
Real-time Price: $16.19 info
Change: +$2.75 (+20%) info
Market Cap: $3.562B info
RLAY
May 19, 2026, 6:00 AM EDT
Source: Reuters
Importance Score:
9
Price at Filing: $12.09
Real-time Price: $16.19 info
Change: +$4.10 (+34%) info
Market Cap: $3.562B info
RLAY
May 05, 2026, 4:15 PM EDT
Filing Type: 10-Q
Importance Score:
8
Price at Filing: $12.55
Real-time Price: $16.19 info
Change: +$3.64 (+29%) info
Market Cap: $3.562B info
RLAY
May 05, 2026, 4:10 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $12.55
Real-time Price: $16.19 info
Change: +$3.64 (+29%) info
Market Cap: $3.562B info
RLAY
May 05, 2026, 4:05 PM EDT
Source: GlobeNewswire
Importance Score:
9
Price at Filing: $12.50
Real-time Price: $16.19 info
Change: +$3.69 (+30%) info
Market Cap: $3.562B info
RLAY
Apr 28, 2026, 4:05 PM EDT
Filing Type: DEF 14A
Importance Score:
7
Price at Filing: $13.04
Real-time Price: $16.19 info
Change: +$3.15 (+24%) info
Market Cap: $3.562B info
Research tools: Filing Impact Index Dilution Tracker Split Calendar Open Datasets